UNLEASH IMMUNO ONCOLYTICS

unleash-immuno-oncolytics-logo

Unleash IO develops oncolytic immunotherapy products shown to be highly specific and efficacious in animal models and human tissue samples. Unleash IO’s leading product, UIO-512, is an oncolytic adenovirus that targets both malignant cells and tumor-associated stroma cells. UIO-512 is armed with GM-CSF, a potent immune-modulatory cytokine, triggering an immune response towards the tumor. UIO-512 lead indication is in ovarian cancer, follow on indications include other solid tumors such as glio... blastoma, melanoma and pancreatic cancer. Promising pre-clinical results in animal models and fresh human samples of ovarian cancers as well as in melanoma were published in top ranked peer-reviewed publications. Unleash IO is raising $3.5 M to conduct a phase I/II clinical trial in ovarian cancer with oncolytic immunotherapy UIO-512.

#SimilarOrganizations #People #Financial #Website #More

UNLEASH IMMUNO ONCOLYTICS

Social Links:

Industry:
Biotechnology Medical Device Therapeutics

Founded:
2015-01-01

Address:
Saint Louis, Missouri, United States

Country:
United States

Website Url:
http://www.unleash.bio

Total Employee:
1+

Status:
Active

Contact:
314-730-0050

Email Addresses:
[email protected]

Total Funding:
3 M USD

Technology used in webpage:
SPF Google Apps For Business Hostgator Mail Oracle Cloud A2 Hosting


Similar Organizations

calimmune-logo

Calimmune

Calimmune is a clinical-stage gene therapy company.

spero-therapeutics-logo

Spero Therapeutics

Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.

Current Employees Featured

ariel-muslera_image

Ariel Muslera
Ariel Muslera CFO @ Unleash Immuno Oncolytics
CFO

daniel-katzman_image

Daniel Katzman
Daniel Katzman CEO @ Unleash Immuno Oncolytics
CEO
2015-01-01

david-t-curiel_image

David T. Curiel
David T. Curiel CSO @ Unleash Immuno Oncolytics
CSO

Founder


david-t-curiel_image

David T. Curiel

Investors List

oncolys-biopharma-inc_image

Oncolys BioPharma

Oncolys BioPharma investment in Venture Round - Unleash Immuno Oncolytics

skandalaris-center-for-interdisciplinary-innovation-and-entrepreneurship_image

Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship

Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship investment in Grant - Unleash Immuno Oncolytics

Official Site Inspections

http://www.unleash.bio Semrush global rank: 5.33 M Semrush visits lastest month: 1.56 K

  • Host name: 69.48.181.160.static.a2webhosting.com
  • IP address: 69.48.181.160
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Unleash Immuno Oncolytics" on Search Engine

St. Louis-based Unleash Immuno Oncolytics Attracts …

LOUIS – St. Louis-based startup Unleash Immuno Oncolytics, which has developed viral-based biologics to attack cancerous tumors, has attracted a major investment from publicly-traded Japanese company Oncolys …See details»

Unleash Immuno Oncolytics - Crunchbase Company …

Details. Industries. Biotechnology. Medical Device. Therapeutics. Headquarters Regions Midwestern US. Founded Date 2015. Founders David T. Curiel. Operating Status Active. …See details»

Unleash Immuno Oncolytics | LinkedIn

Unleash Immuno Oncolytics | 135 followers on LinkedIn. Unleash IO develops oncolytic immunotherapy products shown to be highly specific and efficacious in animal models and human tissue...See details»

Unleash Immuno Oncolytics Company Profile - Craft

Unleash Immuno Oncolytics is an immune-oncology company developing oncolytic viruses that target the stromal layer of metastatic cancers. Its lead product, UIO-623, is …See details»

Local Immunotherapy Startup Attracts $3 Million Investment

Oncolys, a publicly-traded company on the Tokyo Stock Exchange has invested $3 million into Unleash to advance their lead patented programs UIO-512 and UIO-702 toward …See details»

Unleash Immuno Oncolytics' Leadership Team Team - The Org

The leadership team at Unleash Immuno Oncolytics has a history of experience in the biochemistry and healthcare industries. They have worked as CEOs, VPs, …See details»

Unleash Immuno Oncolytics - Funding, Financials, …

$3M. in funding over 2 rounds. Their latest funding was raised on Feb 19, 2018 from a Venture - Series Unknown round. Unleash Immuno Oncolytics is funded by 2 …See details»

Oncolys BioPharma invests in US Biotech Venture Specialized in ...

By Reuters. February 16, 20181:36 AM PSTUpdated 6 years ago. Feb 16 (Reuters) - Oncolys BioPharma Inc. * Says it will enter into an investment and share transfer …See details»

BRIEF—Oncolys buys into Missouri firm to expand …

19-02-2018 Print. Japan’s Oncolys BioPharma has bought a significant share of Missouri, USA-based Unleash Immuno Oncolytics for $3 million, affording around 27% voting …See details»

Unleash Immuno Oncolytics - Innovation

1 Brookings Drive | St. Louis, MO 63130. [email protected]. Twitter. LinkedIn. Sectors. Diagnostics. Energy & Environment. Med Tech. Physical Sciences. Therapeutics. ©2024 …See details»

Combination Therapy for the Treatment of Shingles with an ...

Feb 1, 2023 3 Unleash Immuno Oncolytics Inc., St. Louis, MO 63110, USA. PMID: 37259374. PMCID: PMC9958712. DOI: 10.3390/ph16020226. Abstract. Practically the …See details»

Japan’s Oncolys invests £3m in adenovirus firm Unleash Immuno …

Feb 20, 2018 Matt Fellows. Unleash Immuno Oncolytics, a US firm focusing on the development of viral biologics in the treatment of cancer, has attracted the attention of …See details»

Imre (Imi) Kovesdi - Chief Scientific Officer - Unleash Immuno ...

About. Senior Science Executive with over 30 years in the research, discovery, and development of therapeutic drugs in both large pharmaceutical and biotechnology …See details»

Unleash Immuno Oncolystics - Products, Competitors, Financials ...

Unleash Immuno Oncolystics is a developer of products aimed at stopping cancer. Its first product, UIO-512, is a cancer-killing virus, or oncolytic virus, that targets malignant cells …See details»

Unleash Immuno Oncolytics will move into the Cambridge …

Feb 18, 2016. Biotech startup Unleash Immuno Oncolytics will soon move into the Cambridge Innovation Center in the Cortex innovation district thanks to a small seed …See details»

Oncolys Invests in US Biotech Venture Specialized in …

Overview of the companies. <Unleash> (1) Name Unleash Immuno Oncolytics, Inc. (2) Address 4320 Forest Park Avenue, Saint Louis, MO 63108 USA. (3) Representative …See details»

Unleashing the power of the immune system to fight cancer

At Oncolytics, we are driven to improve the lives of people with cancer by giving them what matters most: more quality time. To do this, we are developing pelareorep, a unique …See details»

Unleash Immuno Oncolytics - Contacts, Employees, Board …

About. Unleash Immuno Oncolytics has 3 current employee profiles, including CFO Ariel Muslera. Contacts. Job Department. Protected Content. CEO. Non-Management , …See details»

UIO 512 - AdisInsight - Springer

Contact your organization’s admin about adding this content to your AdisInsight subscription. Buy a PDF version of the profile. Request a free trial. Unleash Immuno …See details»

Unleash Immuno Oncolytics - Crunchbase

Companies like Unleash Immuno Oncolytics include Nano Precision Medical, Calimmune, and ExCellThera. STipe Therapeutics Aarhus , Midtjylland , Denmark 2 Contacts 11-50 …See details»